Podium to Practice: EHA 2025 – Lymphoma: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
S233 – EFFICACY OF RITUXIMAB-BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH-RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
This program has been made possible through unrestricted support from Eli Lilly, Merck & Roche.
Studies/trials discussed:
S233 – EFFICACY OF RITUXIMAB-BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH-RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.